ProSomnus, Inc. (OSAPQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProSomnus, Inc. (OSAPQ) trades at $0.014 with AI Score 55/100 (Grade B). ProSomnus, Inc. (OSAPQ) is a medical technology company specializing in intraoral devices for obstructive sleep apnea treatment. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for OSAPQ: OSAPQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OSAPQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OSAPQ: the 3 scored disciplines are evenly split. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ProSomnus, Inc. (OSAPQ) Healthcare & Pipeline Overview
ProSomnus, Inc. (OSAPQ) is a healthcare company focused on innovative intraoral devices for obstructive sleep apnea, catering to a diverse range of healthcare practitioners while facing significant financial restructuring challenges.
What Is the Investment Thesis for OSAPQ?
ProSomnus, Inc. operates in a niche market with substantial growth potential, driven by the increasing prevalence of obstructive sleep apnea and the demand for alternative treatments to CPAP devices. The company’s gross margin stands at 50.7%, indicating a strong ability to maintain profitability despite current financial challenges. However, the ongoing Chapter 11 reorganization poses risks that could affect its operational continuity and market share. Key value drivers include the company’s innovative product line and established relationships with healthcare providers, which may facilitate recovery and growth post-reorganization. Additionally, the rising awareness of sleep disorders and the shift towards personalized healthcare solutions present significant catalysts for ProSomnus's future growth. Investors should closely monitor the company's restructuring progress and its ability to leverage market opportunities in the medical devices sector.
Based on FMP financials and quantitative analysis
OSAPQ Key Highlights
Market Cap: $0.00B, indicating current financial distress following bankruptcy filing.
- Profit Margin: -87.1%, reflecting significant operational challenges.
- Gross Margin: 50.7%, showcasing the company's potential for profitability in a recovering market.
- Beta: 0.17, indicating low volatility compared to the broader market.
- Employee Count: 136, highlighting the company's operational scale.
Who Are OSAPQ's Competitors?
OSAPQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings, Inc. | $100.72 | -0.02% | $19.5B | 78 |
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| HOLX Hologic, Inc. | $76.01 | +0.00% | $17.0B | 58 |
| NVCR Novocure | $17.77 | -2.36% | $2.07B | 55 |
| PHG Koninklijke Philips N.V. | $27.72 | +0.36% | $27.1B | 44 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OSAPQ's Key Strengths?
Innovative product offerings tailored to patient needs.
- Strong gross margins indicating potential for profitability.
- Established distribution network among healthcare practitioners.
- Expertise in intraoral device technology.
What Are OSAPQ's Weaknesses?
Current financial distress following Chapter 11 filing.
- Negative profit margin indicating operational challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on a niche market segment.
What Could Drive OSAPQ Stock Higher?
OSAPQ catalyst: Progress in Chapter 11 reorganization may lead to operational restructuring and renewed focus on product innovation.
- Increasing prevalence of sleep apnea drives demand for alternative treatment options.
- Partnerships with healthcare providers could enhance product adoption and visibility.
- Technological advancements in telemedicine may create new market opportunities for ProSomnus's devices.
- Potential expansion into emerging markets as healthcare infrastructure improves.
What Are the Key Risks for OSAPQ?
Financial-distress signal — its Altman Z-Score of -13.25 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Financial instability following Chapter 11 filing poses significant operational risks.
- Intense competition may impact market share and pricing strategies.
- Regulatory challenges could hinder product development and market entry.
- Economic downturns may affect healthcare spending and device adoption.
- Dependence on a niche market segment could limit growth opportunities.
What Are the Growth Opportunities for OSAPQ?
- Growth opportunity 1: The global sleep apnea devices market is projected to reach $6 billion by 2028, driven by rising prevalence rates and increased healthcare spending. ProSomnus can capitalize on this growth by expanding its product line and enhancing distribution channels to reach more healthcare providers.
- Growth opportunity 2: Increasing awareness and diagnosis of sleep disorders present an opportunity for ProSomnus to enhance its market presence. As more patients seek alternative treatments to CPAP, the demand for customized oral appliances is expected to rise, allowing ProSomnus to capture a larger share of the market.
- Growth opportunity 3: The trend towards telemedicine and remote patient monitoring is reshaping the healthcare landscape. ProSomnus can leverage technology to offer telehealth solutions that integrate its devices, providing convenience for patients and expanding its reach to underserved markets.
- Growth opportunity 4: Partnerships with dental and sleep medicine organizations can enhance ProSomnus's visibility and credibility. Collaborations for clinical studies and product endorsements could drive adoption of its devices among healthcare practitioners.
- Growth opportunity 5: Geographic expansion into emerging markets where healthcare infrastructure is improving could provide substantial growth. ProSomnus can explore partnerships or distribution agreements to introduce its products in regions with increasing demand for sleep apnea treatments.
What Threats Does OSAPQ Face?
- Intense competition from established medical device companies.
- Regulatory challenges impacting product development and compliance.
- Economic downturns affecting healthcare spending.
- Potential patent expirations leading to increased competition.
What Are OSAPQ's Competitive Advantages?
- Strong focus on innovation and product customization differentiates ProSomnus from competitors.
- Established relationships with healthcare providers enhance market access.
- Expertise in intraoral device technology provides a competitive advantage.
- Commitment to quality and patient outcomes fosters brand loyalty among practitioners.
- Ability to respond to market trends and patient needs positions the company favorably.
What Does OSAPQ Do?
ProSomnus, Inc. was founded with a mission to revolutionize the treatment of obstructive sleep apnea (OSA) through advanced medical technology. The company specializes in the design, production, and distribution of customized intraoral devices that provide an alternative to traditional Continuous Positive Airway Pressure (CPAP) therapy. Over the years, ProSomnus has developed a strong reputation among healthcare practitioners, including sleep dentists, specialized sleep physicians, general practitioners, and ENT specialists, for its precision-engineered oral appliances. These devices are tailored to meet the specific needs of patients, offering a comfortable and effective solution for managing OSA. The company operates primarily from its headquarters in Pleasanton, California, and has established a robust distribution network to reach various healthcare providers. However, ProSomnus faced significant challenges in May 2024 when it submitted a voluntary petition for Chapter 11 reorganization to the U.S. Bankruptcy Court for the District of Delaware. This move reflects the financial difficulties the company has encountered, which may impact its operational capabilities and market position. Despite these challenges, ProSomnus continues to focus on innovation and quality in its product offerings, aiming to improve patient outcomes and expand its presence in the growing sleep apnea treatment market.
What Products and Services Does OSAPQ Offer?
- Develops advanced intraoral devices for obstructive sleep apnea treatment.
- Manufactures customized oral appliances tailored to patient needs.
- Distributes products through an internal sales division to healthcare practitioners.
- Collaborates with sleep dentists and specialized physicians to enhance treatment options.
- Focuses on innovation and quality in medical technology.
- Aims to improve patient outcomes in sleep apnea management.
How Does OSAPQ Make Money?
- Generates revenue through the sale of intraoral devices and related products.
- Utilizes an internal sales force to reach healthcare providers directly.
- Engages in partnerships with healthcare practitioners to promote product adoption.
- Focuses on customization to meet specific patient requirements, enhancing value.
- Explores opportunities for expansion into new markets and therapeutic areas.
What Industry Does OSAPQ Operate In?
The medical devices industry, particularly in the realm of sleep apnea treatment, is experiencing robust growth driven by increasing awareness of sleep disorders and a shift towards non-invasive treatment options. The global market for sleep apnea devices is projected to grow significantly, with estimates suggesting a CAGR of over 7% in the coming years. ProSomnus, Inc. positions itself within this expanding market by offering innovative intraoral devices that cater to a diverse range of healthcare providers. The competitive landscape includes established players and emerging companies, with ProSomnus focusing on customization and precision to differentiate its offerings.
Who Are OSAPQ's Key Customers?
- Sleep dentists who provide specialized care for sleep apnea patients.
- General practitioners seeking effective treatment options for their patients.
- Specialized sleep physicians who diagnose and manage sleep disorders.
- Ear, nose, and throat specialists involved in the treatment of sleep apnea.
- Integrated healthcare service providers looking for innovative solutions.
Forward Outlook
Wall Street analysts project ProSomnus, Inc. revenue of about $54.4M for fiscal 2026, with EPS near $-0.12.
Earnings Track Record
ProSomnus, Inc. has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 89.4% below estimates on average.
Financial Health
ProSomnus, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.25 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for ProSomnus, Inc. stands at 102.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.7%, showing how much profit it generates from its asset base. A current ratio of 1.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
ProSomnus, Inc. (OSAPQ) Valuation Context
Relative to its peer group, OSAPQ's quantitative score of 55/100 is roughly in line with the peer average of 62/100.
OSAPQ Revenue & Earnings Trend
In Q2 2024, OSAPQ generated $9.1M in top-line revenue, marking a sequential increase of 21.9%. The company recorded a net loss of $15.2M, with diluted EPS of $-0.87.
Company Profile
ProSomnus, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Pleasanton, US. The company is led by CEO Leonard Liptak. OSAPQ has traded publicly since 2021.
OSAPQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insiders seem to be positioning themselves for a potential turnaround, which often precedes positive shifts.
- The community's bullish sentiment is surprisingly resilient, suggesting belief in the company's long-term value.
- Market perception indicates that ProSomnus might be an acquisition target, fueling speculation and optimism.
- Recent developments suggest the company is actively seeking strategic partnerships to bolster its market position.
Bear Case
- Recent insider activity could also signal attempts to salvage investments before further decline.
- Despite some bullish voices, there's a strong undercurrent of concern within the community about the company's viability.
- Market perception suggests ProSomnus faces increasing competition, potentially eroding its market share.
- Developments indicate that ProSomnus is struggling to adapt to changing market conditions, raising questions about its future.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $9M | -$15M | -$0.87 |
| Q1 2024 | $7M | $3M | -$0.02 |
Based on FMP financials and quantitative analysis
OSAPQ Latest News
No recent news available for OSAPQ.
OSAPQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OSAPQ.
Price Targets
Wall Street price target analysis for OSAPQ.
OSAPQ MoonshotScore
What does this score mean?
The MoonshotScore rates OSAPQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Leonard Liptak
CEO
Leonard Liptak has extensive experience in the healthcare and medical technology sectors. He has held various leadership roles in companies focused on innovative medical solutions, contributing to advancements in patient care and treatment options. Liptak's educational background includes degrees in business and healthcare management, equipping him with the skills necessary to navigate complex industry challenges.
Track Record: Under Liptak's leadership, ProSomnus has focused on enhancing its product offerings and expanding its market reach. His strategic decisions have aimed at improving operational efficiencies and fostering innovation within the company, despite the recent financial challenges.
OSAPQ OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. Companies in this tier often face financial or regulatory challenges, which can lead to lower liquidity and higher volatility.
- OTC Tier: OTC Other
- Potential for significant price volatility due to low trading volumes.
- Limited access to financial information may hinder informed investment decisions.
- Increased regulatory scrutiny following the Chapter 11 filing.
- Risk of delisting from OTC markets if compliance issues are not resolved.
- Verify the company's financial health and restructuring progress.
- Assess the management team's track record and industry experience.
- Review product offerings and market demand for sleep apnea devices.
- Investigate competitive landscape and market positioning.
- Monitor regulatory compliance and potential legal challenges.
- Established presence in the healthcare market with a focus on innovation.
- Partnerships with healthcare practitioners enhance credibility.
- History of product development and distribution in the medical device sector.
Common Questions About OSAPQ (Healthcare)
What does the AI Score mean for OSAPQ?
OSAPQ holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. ProSomnus, Inc. (OSAPQ) is a medical technology company specializing in intraoral devices for obstructive sleep apnea treatment. The company is currently navigating financial challenges following a …
What does ProSomnus, Inc. do?
ProSomnus, Inc. specializes in developing and manufacturing advanced intraoral devices designed for the treatment of obstructive sleep apnea. The company focuses on providing customized oral appliances that serve as alternatives to traditional CPAP therapy, catering to a diverse range of healthcare practitioners, including sleep dentists and specialized physicians.
What are the main risks for OSAPQ?
ProSomnus faces several risks, including ongoing financial instability following its Chapter 11 reorganization filing, which may impact its operational capabilities. Additionally, intense competition from established medical device companies poses a threat to market share. Regulatory challenges could further complicate product development, while economic downturns may affect healthcare spending and device adoption rates.
How does ProSomnus, Inc. manage patent expiration risks?
ProSomnus, Inc. actively engages in lifecycle management strategies to mitigate the risks associated with patent expirations. This includes investing in research and development to innovate and enhance existing products, thereby maintaining a competitive edge. Additionally, the company may explore new therapeutic areas and product lines to diversify its offerings and reduce reliance on any single patent.
What are the key factors to evaluate for OSAPQ?
ProSomnus, Inc. (OSAPQ) holds an AI score of 55/100 (moderate). operates in a niche market with substantial growth potential, driven by the increasing prevalence of obstructive sleep apnea and the demand for alternative treatments to CPAP devices. Not financial advice.
How frequently does OSAPQ data refresh on this page?
OSAPQ's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OSAPQ's recent stock price performance?
ProSomnus, Inc. (OSAPQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings tailored to patient needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OSAPQ overvalued or undervalued right now?
ProSomnus, Inc. (OSAPQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OSAPQ before investing?
Before investing in ProSomnus, Inc. (OSAPQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial performance is under scrutiny due to recent bankruptcy filing.